20 March 2019 - No-one can miss the ongoing saga that is the UK’s exit from the European Union.
The uncertainties it has created for patients, clinicians, the NHS and the pharmaceutical industry don’t start from the date the UK leaves (we can’t even be certain when that will be, it seems). The shadow of Brexit arguably started from the day after the referendum.
But just what does it mean for the speed of access to new medicines? One way of looking at this is to explore trends in submissions to the UK’s best-known health technology assessment agencies.